Advancing Disruptive mRNA Vaccines: Opportunity and Obligation
May 4, 2017
Michael Watson, MB ChB, MRCP, AFPM
President, Valera, Moderna’s infectious disease-focused venture
Evan Rachlin, MD
Senior Director of Strategic Planning, Moderna
As physicians by training, we’re often asked by friends and family why we made the decision to jump from clinical care to the biopharmaceutical space. The potential to bring new medicines to patients – medicines that can impact and improve many, many lives – is tantalizing.
What attracted both of us to Moderna specifically was its potential to bring not just one or two new medicines to market – but to possibly launch an entire new class of medicines that could help people impacted by many types of diseases. Go big or go home.